Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Change in Account Payables (2018 - 2025)

Serina Therapeutics' Change in Account Payables history spans 8 years, with the latest figure at $1.0 million for Q3 2025.

  • For Q3 2025, Change in Account Payables rose 112.4% year-over-year to $1.0 million; the TTM value through Sep 2025 reached $1.1 million, up 225.77%, while the annual FY2024 figure was -$1.7 million, 522.65% down from the prior year.
  • Change in Account Payables for Q3 2025 was $1.0 million at Serina Therapeutics, up from $522000.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $1.2 million in Q4 2022 and bottomed at -$1.4 million in Q2 2024.
  • The 5-year median for Change in Account Payables is $93000.0 (2023), against an average of $4111.1.
  • The largest YoY upside for Change in Account Payables was 300.0% in 2024 against a maximum downside of 1258.4% in 2024.
  • A 5-year view of Change in Account Payables shows it stood at -$946000.0 in 2021, then soared by 230.87% to $1.2 million in 2022, then plummeted by 110.5% to -$130000.0 in 2023, then tumbled by 630.0% to -$949000.0 in 2024, then skyrocketed by 210.12% to $1.0 million in 2025.
  • Per Business Quant, the three most recent readings for SER's Change in Account Payables are $1.0 million (Q3 2025), $522000.0 (Q2 2025), and $441000.0 (Q1 2025).